196 related articles for article (PubMed ID: 12439111)
1. Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization.
Croft J; Parry EM; Jenkins GJ; Doak SH; Baxter JN; Griffiths AP; Brown TH; Parry JM
Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1179-86. PubMed ID: 12439111
[TBL] [Abstract][Full Text] [Related]
2. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
3. Genomic alterations in malignant transformation of Barrett's esophagus.
Riegman PH; Vissers KJ; Alers JC; Geelen E; Hop WC; Tilanus HW; van Dekken H
Cancer Res; 2001 Apr; 61(7):3164-70. PubMed ID: 11306503
[TBL] [Abstract][Full Text] [Related]
4. Clonal analysis of a case of multifocal oesophageal (Barrett's) adenocarcinoma by comparative genomic hybridization.
van Dekken H; Vissers CJ; Tilanus HW; Tanke HJ; Rosenberg C
J Pathol; 1999 Jul; 188(3):263-6. PubMed ID: 10419593
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.
Doak SH; Jenkins GJ; Parry EM; D'Souza FR; Griffiths AP; Toffazal N; Shah V; Baxter JN; Parry JM
Gut; 2003 May; 52(5):623-8. PubMed ID: 12692043
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence.
Walch AK; Zitzelsberger HF; Bruch J; Keller G; Angermeier D; Aubele MM; Mueller J; Stein H; Braselmann H; Siewert JR; Höfler H; Werner M
Am J Pathol; 2000 Feb; 156(2):555-66. PubMed ID: 10666385
[TBL] [Abstract][Full Text] [Related]
8. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
[TBL] [Abstract][Full Text] [Related]
9. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
10. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
[TBL] [Abstract][Full Text] [Related]
12. Frequency of the mitochondrial DNA 4977bp deletion in oesophageal mucosa during the progression of Barrett's oesophagus.
Tan BH; Skipworth RJ; Stephens NA; Wheelhouse NM; Gilmour H; de Beaux AC; Paterson-Brown S; Fearon KC; Ross JA
Eur J Cancer; 2009 Mar; 45(5):736-40. PubMed ID: 19211242
[TBL] [Abstract][Full Text] [Related]
13. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
14. Barrett's oesophagus--a pathologist's view.
Fléjou JF; Svrcek M
Histopathology; 2007 Jan; 50(1):3-14. PubMed ID: 17204017
[TBL] [Abstract][Full Text] [Related]
15. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
[TBL] [Abstract][Full Text] [Related]
16. Barrett's esophagus, dysplasia, and adenocarcinoma.
Haggitt RC
Hum Pathol; 1994 Oct; 25(10):982-93. PubMed ID: 7927321
[TBL] [Abstract][Full Text] [Related]
17. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.
Moyes LH; McEwan H; Radulescu S; Pawlikowski J; Lamm CG; Nixon C; Sansom OJ; Going JJ; Fullarton GM; Adams PD
J Pathol; 2012 Sep; 228(1):99-112. PubMed ID: 22653845
[TBL] [Abstract][Full Text] [Related]
18. Barrett's oesophagus: the new endoscopic modalities have a future.
Deviere J
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
[TBL] [Abstract][Full Text] [Related]
19. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
